Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC
Recruiting
N/A
Interventional Study
Nonsmall Cell Lung Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 300 (estimated)
- Sponsor
- Wen-zhao ZHONG · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to evaluate the effectiveness and safety of a locally deployed artificial intelligence (AI) decision-support model in the multidisciplinary team (MDT) process for patients with non-small cell lung cancer (NSCLC).
The main questions it aims to answer :
What is the level of agreement between treatment recommendations generated by the AI model and those made by a …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age ≥ 18 years;
2. MDT (Multidisciplinary Team) discussion deems a systemic treatment plan necessary;
3. Complete clinical, imaging, and molecular pathological data.
Exclusion Criteria:
1. Stage I patients;
2. Diagnosed with a thoracic tumor other than NSCLC;
3. Lack of det…
Contacts